(VIANEWS) – INPOST (INPST.AS), NAVAMEDIC (NAVA.OL), SANDNES SPAREBANK (SADG.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. INPOST (INPST.AS)
37.6% sales growth and 157.68% return on equity
InPost S.A., together with its subsidiaries, operates as an out-of-home e-commerce enablement platform providing parcel locker services in Europe. It operates through four segments: APM (automated parcel machines), To-Door, Mondial Relay, and International Other. The APM segment focuses on the delivery of parcels to automated parcel machines. The To-Door segment delivers parcels using door-to-door couriers. The Mondial Relay segment delivers parcels to automated parcel machines; and operates pick-up drop-off (PUDO) points in France, Spain, Belgium, the Netherlands, Luxembourg, and Portugal. The International Other segment delivers parcels to automated parcel machines in the United Kingdom and Italy. The company also provides fulfilment services; IT services; and e-Grocery, a delivery service for food and FMCG products through InPost Fresh app. InPost S.A. was founded in 1999 and is headquartered in Luxembourg, Luxembourg.
Earnings Per Share
As for profitability, INPOST has a trailing twelve months EPS of €0.22.
PE Ratio
INPOST has a trailing twelve months price to earnings ratio of 43.02. Meaning, the purchaser of the share is investing €43.02 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 157.68%.
Volume
Today’s last reported volume for INPOST is 170389 which is 55.97% below its average volume of 387038.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 11.1% and positive 33.3% for the next.
Sales Growth
INPOST’s sales growth is 29.6% for the ongoing quarter and 37.6% for the next.
More news about INPOST.
2. NAVAMEDIC (NAVA.OL)
22.8% sales growth and 22.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.75.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 21.71. Meaning, the purchaser of the share is investing kr21.71 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.97%.
Volume
Today’s last reported volume for NAVAMEDIC is 4326 which is 86.86% below its average volume of 32925.
Sales Growth
NAVAMEDIC’s sales growth is 11.5% for the present quarter and 22.8% for the next.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr38.00 at 22:20 EST, way under its 52-week high of kr43.60 and way higher than its 52-week low of kr27.80.
More news about NAVAMEDIC.
3. SANDNES SPAREBANK (SADG.OL)
17% sales growth and 8.32% return on equity
Sandnes Sparebank, an independent savings bank, provides a range of banking and investment products to retail and corporate customers in Norway. It operates through three segments: Retail Market, Corporate Market, and Real Estate. The company offers fixed rate deposits, deposit accounts, BSU, and tax withholding and other accounts; child, death, income, critical illness, disability, car, home, cabin, contents, UNG, and other insurance products; and pension solutions. It also provides bank guarantee, overdrafts, leasing, construction and business loans, factoring and invoice sales; fixed interest, mortgage, car, and other vehicle loans, as well as small loans and refinancing, and green loans; bank and credit cards; various loans and guarantees; and mobile and internet banking services. In addition, the company offers real estate brokerage and general investment advisory services. Sandnes Sparebank was founded in 1875 and is headquartered in Sandnes, Norway.
Earnings Per Share
As for profitability, SANDNES SPAREBANK has a trailing twelve months EPS of kr7.99.
PE Ratio
SANDNES SPAREBANK has a trailing twelve months price to earnings ratio of 10.69. Meaning, the purchaser of the share is investing kr10.69 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.32%.
Yearly Top and Bottom Value
SANDNES SPAREBANK’s stock is valued at kr85.40 at 22:20 EST, way under its 52-week high of kr101.00 and higher than its 52-week low of kr81.00.
More news about SANDNES SPAREBANK.
4. TIPIAK (TIPI.PA)
13.7% sales growth and 6.82% return on equity
Tipiak Société Anonyme, a food company, manufactures prepared food products, frozen ready-meals, pastry products, groceries, and crusty bread products. The company offers groceries, such as breadcrumbs, cereals, couscous, croutons, Japanese pearls, potato starch, quinoa, and tapioca; frozen products, including savory products, appetizers, and side dishes with grains; and frozen sweet products comprising macarons, mini eclairs, and petits fours. It sells its products in France, England, and the United States. The company was founded in 1830 and is based in Saint-Aignan-Grandlieu, France.
Earnings Per Share
As for profitability, TIPIAK has a trailing twelve months EPS of €4.35.
PE Ratio
TIPIAK has a trailing twelve months price to earnings ratio of 14.02. Meaning, the purchaser of the share is investing €14.02 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.82%.
Volume
Today’s last reported volume for TIPIAK is 8 which is 70.37% below its average volume of 27.
Sales Growth
TIPIAK’s sales growth is 13.7% for the present quarter and 13.7% for the next.
Yearly Top and Bottom Value
TIPIAK’s stock is valued at €61.00 at 22:20 EST, way below its 52-week high of €70.00 and way above its 52-week low of €49.60.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.9%, now sitting on 239.37M for the twelve trailing months.
More news about TIPIAK.
